Imperial Innovations and the University of Oxford join a group of corporates and venture firms backing the medical diagnostic company.
Imperial Innovations and the University of Oxford join US-based materials company the Dow Chemical Company and Kaiser Permanente Ventures, the corporate venturing unit of US-based healthcare group Kaiser Permanente, in a syndicate investing $28m in Oxford Immunotec, a medical diagnostic company . The round was led by Imperial Innovations and Invesco Perpetual and also backed…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
